Fairvalue-Calculator Fairvalue-Calculator
EN DE

Virax Biolabs Group (VRAX) Fair Value & Analysis

Healthcare · US · Market cap $2.6M

Price$0.1350
Fair Value$0.2100
Upside+55.6%
Quality90/100
Evidence: Low Range $0.1400 – $0.2600

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Virax Biolabs Group (VRAX) currently trades at $0.1350, while our model-based Fair Value estimate is $0.2100 — implying the stock looks roughly 55.6% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, c…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Virax Biolabs Group (VRAX) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.2100 versus a price of $0.1350 — about +56% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VRAX?
Our 21-model fair value for Virax Biolabs Group is $0.2100 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1350.
What is the quality score of VRAX?
Virax Biolabs Group has a Quality Score of 90/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.